Premium
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia
Author(s) -
Visentin Andrea,
Briani Chiara,
Imbergamo Silvia,
Frezzato Federica,
Angelini Annalisa,
Fedrigo Marny,
Cacciavillani Mario,
Altinier Sara,
Piazza Francesco,
Semenzato Gianpietro,
Adami Fausto,
Trentin Livio
Publication year - 2018
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2480
Subject(s) - idelalisib , medicine , rituximab , amyloidosis , chronic lymphocytic leukemia , immunoglobulin light chain , al amyloidosis , dyscrasia , immunology , pathology , antibody , ibrutinib , plasma cell , leukemia
Light chain amyloidosis is characterized by the progressive deposition of immunoglobulin light chains into the extracellular tissue, leading to organ dysfunction. Usually, it is associated with an underlying clonal plasma cell dyscrasia and rarely with chronic lymphocytic leukaemia. Herein, we described the first report of a patient with relapsed chronic lymphocytic leukaemia harbouring TP53 abnormalities who developed, histologically proven, systemic light chain amyloidosis who was treated with the PI3K inhibitor, idelalisib, and rituximab. Unfortunately, the patient had sudden death during sleep, likely caused by arrhythmia secondary to amyloid cardiomyopathy. Idelalisib was at least effective in reducing secretory free light chain, chronic lymphocytic leukaemia burden, and to improve the survival of patient.